Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study

NCT01604811 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT01604811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01604811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2013
Enrollment
206 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)